A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 4, 2014, Pages 180-189

  Atkinson, Sarah D ^a   Prakash, Apurva ^b   Zhang, Qi ^b   Pangallo, Beth A ^b   Bangs, Mark E ^b   Emslie, Graham J ^c   March, John S ^d  

^a Finger Lakes Clinical Research   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DULOXETINE; FLUOXETINE; PLACEBO; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADJUSTMENT DISORDER; ADOLESCENT; ADOLESCENT DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOMUTILATION; CHILD; CHILDHOOD DISEASE; CHILDREN DEPRESSION RATING SCALE; COLUMBIA SUICIDE SEVERITY RATING SCALE; COMPRESSION FRACTURE; CONTROLLED STUDY; CONVERSION DISORDER; CONVULSION; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EPILEPSY; FAINTNESS; FEMALE; GASTRITIS; HUMAN; HYPOMANIA; LONG TERM CARE; LOW DRUG DOSE; LYMPHADENITIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PILONIDAL SINUS; PNEUMONIA; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; SOCIAL PHOBIA; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; ULNA FRACTURE; VITAL SIGN; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; SUICIDE; TREATMENT OUTCOME;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; SUICIDE; THIOPHENES; TREATMENT OUTCOME;

EID: 84901254995     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0146     Document Type: Article

References (19)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Cymbalta Full Prescribing Information. http://pi.lilly.com/us/cymbaltapi. pdf. Accessed March 1, 2014
3. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215, 2002
4. Emslie G, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS: A double-blind, efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:170-179, 2014
5. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebocontrolled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037, 1997
6. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976
7. Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, Galil N, Kaplan S, Busner J, Nilsson ME, Brown EB, Jacobson JG: Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-Than-complete response to nine-week treatment with fluoxetine 10-20 mg: A pilot study. J Child Adolesc Psychopharmacol 16:207-217, 2006
8. Kenward MG, Roger JH: Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53:983-997, 1997
9. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB: Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30: 445-60, 2005
10. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: Treatment for Adolescents With Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807-820, 2004
11. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents: Update on the 1996 task force report on high blood pressure in children and adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 114:555-576, 2004
12. National Research Council: The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press; 2010
13. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ: The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266-1277, 2011
14. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007
15. Poznanski EO, Cook SC, Carroll BJ: A depression rating scale for children. Pediatrics 164:442-450, 1979
16. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R: Preliminary studies of the reliability and validity of the Children's Depression Rating Scale. J Am Acad Child Psychiatry 23:191-197, 1984
17. Prakash A, Lobo E, Kratochvil CJ, Tamura RN, Pangallo BA, Bullok KE, Quinlan T, Emslie GJ, March JS: An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol 22:48-55, 2012
18. Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ: Use of effect size to determine optimal dose of duloxetine in major depressive disorder. J Psychiatr Res 41:311-318, 2007
19. Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, Milo KM, Stock SL, Wilkinson B: Reliability and validity of the Mini International Neuropsychiatric interview for Children and Adolescents (MINI-KID). J Clin Psychiatry 71:313-326, 2010